Loading...
Loading...
ACRS| Name | Value |
|---|---|
| Revenues | 4.3M |
| Cost of Revenue | 2.4M |
| Gross Profit | 1.9M |
| Operating Expense | 12.4M |
| Operating I/L | -10.5M |
| Other Income/Expense | 2.9M |
| Interest Income | 2.0M |
| Pretax | -7.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -7.6M |
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates for immune-inflammatory diseases. The company operates through two segments: Therapeutics, which identifies and develops novel therapies for immuno-inflammatory diseases, and Contract Research, providing laboratory services. Aclaris is developing Zunsemetinib, an MK2 inhibitor for rheumatoid and psoriatic arthritis and Hidradenitis suppurativa, as well as ATI-1777, a soft JAK 1/3 inhibitor for atopic dermatitis. Additionally, the company is working on ATI-2138 for T cell-mediated autoimmune diseases, a Gut-Biased Program for inflammatory bowel disease, and ATI-2231 for pancreatic and metastatic breast cancer.
